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Summary The technique of alkaline elution has been adapted for the study of drug-induced DNA cross-link
formation in vivo. Pretreatment with misonidazole (MISO) enhances the number of cross-links formed in a
fibrosarcoma and in the spleen and gut of mice for periods up to 48h following a single injection of
melphalan (MEL). The tumour was sensitized by a greater factor (2.05) than either of the normal tissues
(enhancement factor 1.4-1.5). This enhancement did not appear to be related to inhibition of the repair of
actual cross-links. Rather, the effect was explicable in terms of one of two alternative models. Firstly, MISO
pretreatment could result in a greater amount of binding of MEL to DNA at early times after injection. This
may be the result of altered pharmacokinetics of MEL, or of enhanced intracellular uptake of MEL due to
MISO pretreatment. Secondly, MISO may exert its affect by inhibition of the repair of cross-links or
monoadducts at early times post-injection, which would not be observed in this study. The possible
involvement of glutathione depletion in chemosensitization by MISO was investigated by comparison with the
effect of diethyl maleate (DEM), a known thiol-depleting reagent. Glutathione depletion, while perhaps being
important, could not account for all of the effects observed.
The hypoxic cell radiosensitizer misonidazole
(MISO) has recently been shown to sensitize
mammalian cells and tissues to the effects of a
wide variety of anticancer drugs both in vitro
(Stratford et al., 1980; Roizin-Towle & Hall, 1981)
and in vivo (e.g., Rose et al., 1980; Mulcahy et al.,
1981; Martin et al., 1981; Twentyman, 1981). In
general, in vivo studies conducted in experimental
animals with DNA cross-linking agents, such as
melphalan (MEL) and cyclophosphamide, have
been encouraging in thfat normal tissue toxicity is
usually less markedly enhanced than is the tumour
response, as indicated by the delay of tumour
regrowth or decreased tumour cell survival assayed
in vitro. MISO enhancement ratios are usually
between 1.2-3.1 for tumour response and between
1.2-1.9 for normal tissue toxicity, such as
myelosuppression or low white blood cell count
(Fowler, 1982). Phase I clinical studies of MISO in
combination with DNA cross-linking agents are
currently in progress (Rimondi et al., 1982; Klein et
al., 1982).
Several possible processes have been implicated in
the mechanism of chemosensitization. These
include: alterations in pharmacokinetics and meta-
bolism (Stephens et al., 1981; Tannock, 1980;
Clutterbuck et al., 1982), selective toxicity towards
hypoxic or non-cycling cells (Sutherland, 1974), the
generation and fixation of free-radical intermediates
(Clement et al., 1980), inhibition of the repair of
potentially lethal damage (PLD) (Law et al., 1981;
Martin et al., 1981; Siemann & Mulcahy, 1982), or
reduced levels of intracellular sulphydryl-containing
compounds such as glutathione (GSH) (Taylor et
al., 1982a; Roizin-Towle et al., 1982) which are
involved in detoxification of electrophilic drugs
such as MEL and are also free-radical scavengers.
Although hypoxia is a prerequisite for in vitro
sensitization (Stratford et al., 1980; Roizin-Towle &
Hall, 1981), its exact significance in terms of
normal tissue versus tumour toxicity in vivo is
unclear (Tannock, 1980; Law et al., 1981).
In this paper, it has been our intention to observe
the effects of MISO on the activity of MEL in vivo
at the molecular level. Using the alkaline elution
technique devised by Kohn (Kohn, 1979; Kohn et
al., 1976), adapted for use in vivo with a
microfluorimetric DNA assay (Cesarone et al.,
1979), it has been possible to quantitate the cross-
linking activity of MEL in both normal tissues and
in a fibrosarcoma. In particular, the questions we
have addressed in this study are:
(1) Does pretreatment with MISO potentiate
the cross-linking activity of a drug such as
melphalan? (2) Is there a realistic therapeutic index
from such drug combinations, i.e., is normal tissue
toxicity (as related to the formation and removal of
cross-links) significantly less enhanced than the
antitumour effect? (3) Can we discriminate between
the mechanisms discussed above for chemo-
sensitization?
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Materials and methods
Mice and tumours
C3Hf/Kam mice between 12-16 weeks of age, from
an SPF breeding colony, were used in this study.
The fibrosarcoma (FSa) was originally induced in
C3H mice by methylcholanthrene (Suit & Suchato,
1967). Fourth and 5th isotransplant generations
were kept in liquid nitrogen, and experiments were
performed with the 7th generation. Tumours were
grown from 5 x 105 cells injected into the hind legs
of mice and were considered of suitable size when
they reached - 12mm in diameter.
Preparation oftissue suspensions
Animals were killed at various times following
treatment, and the tissues under study were
removed and immersed in ice-cold Pucks Saline A,
PSA (8.0g NaCl, 0.4g KCI, 1.0g glucose, and
0.35g NaHCO3 per liter), containing 5mM EDTA.
Necrotic and haemorrhagic tissue was separated
from the viable tumour tissue and discarded. The
remaining tissue was finely minced with ophthalmic
scissors and syringed 6 x with 8ml of PSA via a
15-ga. needle, then filtered through stainless steel
mesh (200 wires in-1) or several layers of cotton
gauze. The tumour suspension was washed twice by
sedimentation at 2000rpm for Omin in a
refrigerated Beckman TJ-6 centrifuge and
resuspended in fresh PSA. Cell integrity was
routinely 95% as determined by trypan blue
exclusion and phase contrast microscopy, and the
yield of viable cells was _108g-1 of excised
tumour.
Spleen cells were obtained by cutting the spleen
capsule and teasing out the cells with curved
ophthalmic scissors. The cells were suspended in
10ml of PSA by vigorous pipetting, and washed
twice by centrifugation and resuspension as above.
Gut suspensions were prepared by removing the
first 10cm of the small intestine below the stomach.
Undigested material in the lumen was removed by
flushing with cold PSA via a 15-ga. needle. The gut
was then cut open along its length and the mucosal
layer was gently separated by scraping with a glass
slide in a petri dish. The cells were suspended in
PSA by very gentle pipetting and filtered through
cotton gauze.
For most tissues, the number of cells could be
counted with a haemacytometer. Because of the
difficulty in preparing single-cell gut suspensions
without damaging the cells, 1.Oml of the suspension
was used for alkaline elution analysis.
Alkaline solution
The alkaline elution technique applied to in vitro
systems has been described in detail (Kohn, 1979;
Kohn et al., 1976). Modifications to adapt the
technique for use with murine tissues are discussed
below.
About 6-8 x 106 cells were impinged onto a 47-
mm diameter, 0.8 im pore polycarbonate filter
(Nucleopore Corp.) They were then washed with
10ml of cold PSA, and subsequently lysed with
10ml of a lysis solution (2MNaCl, 0.04M
tetrasodium EDTA, 0.2% Sarkosyl, final pH 10.0).
The filter was washed with 5-10ml of 0.02M
tetrasodium EDTA, pH 10.3, and the DNA
was eluted in the dark with 0.1 M
tetrapropylammonium hydroxide containing 0.02M
EDTA (free acid), pH 12.1, at a constant flow rate
of 0.04mlmin-. Fractions were collected every
90min for 15h. Any DNA retained on the filter
was removed by heating to 60°C for 30min and
vortexing extensively in 5ml of the pH 10.3 EDTA
wash solution. DNA remaining in the filter holder
or barrel was recovered by flushing vigorously with
5ml of EDTA wash solution.
For each experiment, a blank column with filter,
identical to the alkaline elutions described above
but with no cells added, was run to correct for
background fluorescence (see following section).
Fluorimetric assay ofDNA
The relative DNA concentration in each fraction
was determined using the fluorescent dye Hoechst
33258 (Cesarone et al., 1979). A 1-ml aliquot was
withdrawn from each fraction, including the filter
and wash solutions, and transferred to a 13 x
100mm glass culture tube. Each sample was
neutralized with 0.4ml of 0.2M KH2PO4, and the
volume adjusted to 2ml with 0.6ml of distilled
water. Finally, 1 ml of Hoechst dye (1.5 x 10-6 M)
in standard saline citrate was added and the tubes
were vortexed. The fluorescence was determined
using an Amino SPF-125 spectrofluorometer with
the excitation wavelength set at ca. 350nm and the
emission at ca. 460nm (the actual wavelengths were
adjusted to give the maximum signal for a sample
of high DNA concentration). This same procedure
was performed on the blank (cell-free) experiment,
and the background so determined was subtracted
from the emission of each fraction in the actual
elution experiment to give the corrected
fluorescence intensity. The "total fluorescence" of
each fraction is defined as the product of the
corrected fluorescence intensity and the volume of
that fraction.
Calculation ofcross-linkingfactors
Cross-link factors (CLF) were estimated as follows.
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single-cell suspensions were irradiated on ice with a
dose of 5Gy of X-rays from a General Electric
Maximar 250 KVP X-ray machine (dose rate,
3.53Gymin-'). This treatment introduces a
uniform amount of single-strand breaks into the
DNA, which is consequently eluted from the filter
at a rate faster than that for the non-irradiated
control (see Figure 1). The cells were held on ice
following irradiation to prevent repair of the strand
breaks. The presence of DNA cross-links results in
a decrease in the rate ofelution of the DNA relative
to a 5-Gy irradiated control tissue with no drug
treatment (e.g. see the curves shown in Figure 1 for
MEL or MEL+MISO treated samples with
the standard 5-Gy dose). The CLF at a particular
eluted volume v is determined from:
CLF=logf5(v)/f0(v) logf.(v)ffo(v)
where f0(v), f5 (v) and f,(r) are respectively the
fraction of DNA remaining on the filter for the
nonirradiated control, the 5-Gy control, and the 5-
Gy drug-treated sample at volume v; thus a CLF of
1.0 is indicative of no cross-link formation. Unless
otherwise stated, data are the average of >3
separate experiments, and the s.e. is displayed with
the mean value.
Glutathione assay
Tissue concentrations of reduced glutathione were







using the dye o-pthalaldehyde (Hissin & Hilf, 1976).
Results obtained with this assay were identical to
those using Ellman's reagent (see Wang et al.,
1980, for details of this procedure).
Drugs and dyes
Misonidazole (MISO, Hoffman-La Roche Inc.)
was dissolved in saline at 45°C with periodic
agitation for 10-15min prior to use.
Melphalan (1-phenylalanine mustard, MEL) NSC
no. 88806, Lot 8A-0061, was obtained from the
National Cancer Institute (NCI). MEL (5mg) was
dissolved in 20ml of 0.85% saline and vortexed
extensively for 10-15min before use.
Cis-dichlorodiammineplatinum (II) (cis-platinum,
cis-DDP) NSC no. 119875, Lot no. 37-3 was
obtained from the NCI. It was dissolved in saline-
mannitol (1% mannitol containing 1 gI ofNaCl).
Hoechst 33258 (Aldrich), o-phthalicdicarb-
oxaldehyde, OPT (Aldrich), reduced glutathione,
GSH (Calbiochem), and diethyl maleate, DEM
(Aldrich) were used as received. DEM was dissolved
in sesame oil. Unless otherwise stated, all drugs were
injected i.p.
Results
Typical alkaline elution profiles from an experiment
in which MISO (1 mgg 1) was injected 30min prior
to MEL (5mgkg-1, 12h exposure) are shown in
Figure la and lb for FSa and spleen, respectively.
Volume eluted (ml)
Figure 1 Typical alkaline elution profiles for (a) tumour and (b) spleen showing non-irradiated (V) and 5-
Gy irradiated (A) controls (no drug treatment), and tissues from mice treated with MEL (5mgkg-', i.p.,
12h) in vivo, with (0) or without (0) pretreatment with MISO (1 mgkg-1, i.p., 0.5h), and subsequently
exposed to 5 Gy of X-rays. Irradiation of the tissue suspensions was performed in vitro on ice just prior to
analysis by alkaline elution.
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The slower rate of elution for the combined drug
schedule relative to MEL alone is indicative of a
greater degree of cross-linking in the MISO-
pretreated animal for each tissue studied. MISO
alone for periods from 0.5-6h produced no
detectable strand-breaks or cross-links in any tissue;
elution profiles for both 0-Gy and 5-Gy doses
(irradiated in vitro) were essentially identical to
those from respective untreated control animals.
In order to establish cross-linking levels in tissues
treated with MEL alone in vivo, the kinetics of the
formation and repair of cross-links were analyzed in
FSa, gut and spleen. In both tumour (Figure 2),
spleen (Figure 3), and gut (Figure 4) the level of
cross-linking increased gradually, reaching a
maximum between 6-16h and then decreasing
thereafter, presumably due to repair and/or cell
turnover. The relative amount of cross-linking in
each tissue was assessed by integration of the curves
Time post-injection (h)
Figure 2 Time course of the formation and
disappearance of DNA cross-links produced in
fibrosarcoma after i.p. injection of MEL (5mgkg-')









Figure 3 Time course of the formation and
disappearance of DNA cross-links in spleen after i.p.
injection of MEL (5mgkg-') with (0) and without






Figure 4 Time course of the formation and
disappearance of DNA cross-links in jejunum after i.p.
injection of MEL (5mgkg-1) with (0) and without
(@) pretreatment with MISO (1 mgg-', i.p., 0.5h).
shown in Figures 2-4 between 0-24h. These data
are included in Table 1, values being normalised to
the lowest observed degree of cross-linking (i.e. gut).
FSa exhibited a greater degree of cross-linking at
each time point with MEL treatment alone than
did the normal tissues. Thus there appears to be an
intrinsic difference in cross-link formation between
tumour and normal tissues treated with MEL
alone.
The kinetics of the formation and disappearance
of the cross-links induced by a single dose of MEL
(5mgkg-1) after a 30min pretreatment with MISO
(1mgg-') are also shown in Figures 2-4 for FSa,
spleen, and gut, respectively. At all times between
6-72h, more cross-linking was detected in all tissues
from the MISO-treated animal. For gut (Figure 4),
data at <6h were subject to large variations, but at
all times >6h an enhancement by MISO was
observed. The overall enhancement was calculated
from the ratio of the areas under the graph of CLF
versus time between 0-24h in the presence and
absence of MISO. This time period was chosen in
order to minimize errors due to cell turnover, and
also since cross-link repair processes in vitro appear
to be completed by this time (Taylor et al., 1982b;
Meyn et al., 1982). The calculated enhancement
factors (Table I) were 2.0 (FSa), 1.5 (spleen), and 1.4
(gut). Thus, in addition to showing the greatest
degree of cross-linking when treated with MEL
alone, the FSa also exhibited a greater MISO
enhancement than did the normal tissues studied. It
is interesting that for each tissue, the CLF values
for MEL alone or for MISO plus MEL did not
return to their control values even as late as 48h
post-injection, indicating some fraction of cross-
links that are not repaired.
We also studied.the effect of MISO pretreatment
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Table I Relative cross-linking* and enhancement factors
in tissues from mice treated with MEL (5mgkg-') with
or without pretreatment with MISO (1 mgg l).
Relative cross-linking*
Tissue MEL MISO+MEL Enhancement
Tumour 1.27 2.6 2.05
Spleen 1.01 1.51 1.5
Gut 1.0 1.4 1.4
*Determined from the area under the curve of CLF versus
time between 0-24h (see text). Values are normalized to
the lowest observed degree of cross-linking, i.e., a value of
1.0 is assigned to gut treated with MEL alone.
agent, cis-platinum. In contrast to our results
with MEL, a 30-min preincubation with MISO
(1mgg-) did not significantly enhance the cross-
linking of cis-DDP (4mgkg-1, i.p.) at either 6h or
24h post-injection in either tumour or spleen (Table
II), the DNA from the combined drug-treated
animals eluting at essentially the same rate as from
those treated with cis-DDP alone.
Since it was anticipated that intracellular
sulphydryl-containing compounds may be involved
in the action of MISO at the molecular level, we
investigated the possible involvement of GSH
depletion in MISO chemosensitization. The
nucleophilic GSH is involved in the elimination of
toxic electrophilic species such as the nitrogen









al., (1980), have implicated the possible involvement
of free-radical intermediates in the MISO
potentiation of MEL and other drugs, and GSH is
known to act as an intracellular free-radical
scavenger. The effect of MISO was compared with
that of diethyl maleate, DEM, a reagent that has
been shown to selectively deplete GSH levels both
in vitro and in vivo (Bump et al., 1982). The
Table II Cross-linking factors at various times post-
injection for mice treated with cis-DDP (4mgkg-1) with
or without a 30min pretreatment with MISO (1 mgg 1).
CLF
Time before
Pretreatment killing Tumour Spleen
None 6h 1.64+0.23 1.64
MISO 6h 1.48+0.25 1.60
None 24h 1.30+0.18 1.16+0.02
MISO 24h 1.40+0.22 1.17+0.04
concentration of reduced glutathione (pym GSH g-1
of excised tissue) in spleen, liver and tumour as a
function of time after i.p. injection of MISO or
DEM are shown in Figure 5. Results for liver are
included as controls since DEM has been shown to
cause marked depletion of hepatic GSH in mice
(e.g., see Gurtoo et al., 1981) and in rats (Younes &
Siegers, 1981). DEM (700mgkg-1) resulted in large
GSH depletion in liver (to 16% of control value at
N I
Time post-injection (h)
Figure 5 Concentration of reduced glutathione in fibrosarcoma (-), spleen (0) and in liver (0) of mice as a
function of time after injection with MISO (1 mgg-', i.p.) or DEM (700mgkg-', i.p.).200 D. MURRAY & R.E. MEYN
1 h) and somewhat less in spleen (to 64% at 1 h) and
tumour (to 68% at 2h). MISO (1mgg-1) also
depleted GSH in liver (to 62% of a control at 1 h)
and tumour (to 75% at 2h), but did not affect spleen
up to 6h post-injection. When administered 30min
prior to MEL (5mgkg-1), DEM (700mgkg-1)
caused a pronounced enhancement of cross-linking
in both spleen and tumour at 6h post-injection
(Table III).
Table III Cross-linking factors at 6h post-
injection for mice treated with MEL (5mgkg-1)







The use of combinations of MISO with alkylating
agents was originally proposed in the hope of
utilizing the selective toxicity of MISO toward
hypoxic cells to kill that fraction of the tumour that
was apparently resistant to chemotherapy.
However, it is now generally accepted that MISO
does in fact sensitize cells to the cytotoxic effects of
a wide variety of antitumour drugs, especially
alkylating agents, the response being greater than
would be predicted from a simple additive effect of
the two drugs (see the reviews by Millar, 1982, and
McNally, 1982). As mentioned earlier, the
mechanism of this chemosensitization effect is still
very unclear, although there is general agreement
that the tumour response is somewhat more
pronounced than that of normal tissues.
If we assume that MEL-induced cross-links are
responsible for its cytotoxicity, the results shown
here suggest that it is possible to account in full
for the increased cytotoxicity and differential effects
of MISO on tumour and normal tissue solely on
the basis of the enhanced cross-linking observed
without considering any selective killing of hypoxic
cells. The enhancement in tumour (by a factor of
2.0 Table I) and in normal tissues in the tumour-
bearing animal (by a factor of 1.4-1.5, Table I) is
comparable to the enhancement observed for
tumour response and normal tissue toxicities in
other studies (see Fowler, 1982). The greater
enhancement of FSa, combined with the
observation (Table I) that the tumour is
intrinsically more sensitive than two normal tissues
to cross-linking by MEL, confirms that a realistic
therapeutic index may be achieved using combined
drug treatments, especially once the scheduling and
dosage are optimized. The scheduling of the drug
treatments in this work was selected on the basis of
a previously published study (Rose et al., 1980), so
that comparisons with survival and tumour
regrowth data could be made.
The kinetics of MEL-induced cross-link
formation and disappearance (Figure 2 and Figure 3),
with the CLF increasing with time up to a
maximum at -12h and then slowly decreasing, are
similar to results observed with mouse leukaemia
L1210 cells (Ross et al., 1978) and with CHO cells
(Taylor et al., 1982b) in vitro. This suggests that the
mechanism of MEL induced cross-link formation in
vivo and in vitro are essentially the same, possibly
reflecting a slow second step in the formation of the
actual cross-link subsequent to the production of a
monofunctionally bound MEL species. The high
level of residual cross-links at times >24h that we
observed here for each tissue was also found in
vitro with the L1210 cell line (Ross et al., 1978),
whereas with cultured CHO cells most of the MEL
cross-links were repaired by 24h (Taylor et al.,
1982b).
The mechanism of chemosensitization and the
enhancement of cross-linking drugs by MISO
remains to be elucidated. However, if the
cytotoxicity of MEL is a reflection of the DNA
cross-linking it produces, then it seems reasonable
that repair of PLD in MEL treated tissues may be
associated with the repair of these lesions or their
monoadduct precursors; MISO pretreatment could
therefore result in enhanced cross-linking if it
inhibited such repair processes. MISO has been
reported to inhibit the repair of MEL- and
cyclophosphamide-induced PLD in several tumour
lines (Law et al., 1981; Martin et al., 1981), while a
tumour in which no repair of PLD could be
observed showed a markedly lower degree of
MISO-chemosensitization (Martin et al., 1981).
Siemann & Mulcahy (1982) have shown that for a
series of nitrosoureas the MISO enhancement ratios
correlate with the extent of PLD repair inhibition.
However, in other tumours in which there was no
apparent repair of PLD, MISO has still been
observed to enhance the effect of MEL (Rose et al.,
1980) and cyclophosphamide (Siemann & Mulcahy,
1982). Similarly, in vitro studies have shown that
enhanced MEL cytotoxicity is not related to
inhibition of PLD repair (Horsman et al., 1982).
Because of the low levels of cross-linking observed
here with MEL when given i.p., and also the large
fraction of residual cross-links, it is somewhat
difficult to assess the extent of cross-link repair,
except in the case of the tumour (Figure 2) where
some repair is evident between 12-20h and thisMECHANISM OF CHEMOSENSITIZATION IN VIVO 201
does not appear to be altered by MISO
pretreatment. Taylor et al., (1982b) have shown that
MISO enhances MEL-induced cross-link formation
by a factor of -4 in vitro, but that these cross-links
are essentially all removed by 24h with or without
MISO pretreatment, again there being no evidence
for inhibition of cross-link repair. In preliminary in
vivo experiments where MEL was administered iv,
much greater cross-linking factors were observed
(CLF >3 for FSa) and most of these cross-links
had been removed by 24h in both FSa and in
normal tissues (Jenkins & Meyn, unpublished data).
Experiments are in progress to establish whether
MISO inhibits these repair processes.
The observation that MISO pretreatment results
in increased levels of MEL-induced cross-links at
each time point, without apparently altering the
kinetics of their formation of their removal (Figures
2-4), is best explained by one of two alternative
models:
1. The more obvious explanation is that MISO
pretreatment could increase the initial amount of
MEL bound to DNA prior to the formation of
cross-links, via mechanisms involving alterations
in drug pharmacokinetics or enhanced
intracellular uptake. The monofunctionally
bound MEL species referred to above would
then be subsequently expressed as cross-links in
the time period up to 12h post-injection. Any
mechanism that would increase the extent of
MEL binding at early times would suitably
account for both the enhancement and the
observed kinetics. Pharmacokinetic alterations
could result in more effective delivery of MEL,
producing a higher initial concentration of such
DNA/MEL species discussed above. In support
of this mechanism, MISO has been reported to
increase both the serum retention time and peak
serum level of MEL in mice (Clutterbuck et al.,
1982). While we see no evidence at any time
point for alterations in the kinetics of actual
cross-link formation after MISO-pretreatment,
there is nothing in the data presented that can
rule out contributions from pharmacokinetic
effects since these would operate on a much
faster time scale than that for the slower
formation of the cross-links themselves. MISO
may also affect the cellular uptake of MEL by
altering membrane permeability.
2. However attractive, this first model cannot
account satisfactorily for the apparent inhibition
of PLD repair by MISO in certain systems.
While MISO does not seem to affect the repair
of cross-links on the longer time scale which we
have observed, it may act by inhibiting repair in
the first few hours post-injection or by inhibiting
repair of some intermediate DNA/MEL species
such as monoadducts that subsequently form
cross-links, and thus increase the overall CLF.
Preincubation with MISO did not enhance the
cross-linking activity of cis-DDP (Table II).
Although MISO has been found to enhance cis-
DDP cytotoxicity in vitro (Stratford et al., 1980;
Roizin-Towle & Hall, 1981), there is no apparent in
vivo sensitization (Rose et al., 1980; Clement et al.,
1980; Stephens et al., 1981). As noted previously
(Clement et al., 1980), this may be due to the fact
that cis-DDP exerts its cross-linking effect via a
coordination mechanism that does not involve free-
radical intermediates (Rosenberg, 1979).
Since MISO is known to deplete intracellular
levels of GSH in hypoxic cells (Varnes et al., 1980;
Taylor et al., 1982a), we also investigated the
possible involvement of glutathione in chemo-
sensitization. Both DEM and MISO did cause
a significant alteration of GSH levels (Figure
5), but this was tissue specific and possibly related
to the requirement of hypoxia for MISO but not for
DEM to deplete GSH in vitro (Varnes et al., 1980).
Although the enhancement of MEL cross-linking by
DEM in both spleen and tumour (by a factor of 2.0
and 1.8, respectively, see Table III) may be related
to GSH depletion, the lack of GSH depletion by
MISO in spleen despite the observed enhancement
of MEL by MISO (by a factor of 1.5) in this tissue
suggests that, while GSH depletion may play a part
in chemosensitization, it is unlikely to account for
the whole effect. Although MISO has been found to
deplete GSH in hypoxic cells, depletion could only
account for part (15-20%) of the increased
cytotoxicity of MEL (Taylor et al., 1982a., b). The
lack of GSH depletion by MISO in spleen is
probably indicative of a relative absence of hypoxic
cells therein.
In summary, we have shown that pretreatment
with misonidazole increases drug-induced cross-
linking in tissues in vivo after subsequent exposure
to alkylating agents such as melphalan. However,
because of the relatively slow rates of cross-link
formation and removal with this drug, it is difficult
to discriminate between several possible
mechanisms for this effect. Studies using drugs with
which cross-link formation is expressed almost
immediately in vitro, such as mitomycin C (Meyn et
al., 1982) or nitrogen mustard (Ross et al., 1978) are
currently being investigated so that events occurring
at much earlier times may be observed in vivo.
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